Proceeds slated for clinical development and related manufacturing
By Devika Patel
Knoxville, Tenn., Feb. 18 – Atara Biotherapeutics, Inc. said the underwriters for its public offering of stock opted to exercise the deal’s $9.82 million greenshoe in part for total proceeds of $74.65 million. The deal was announced on Jan. 28 and priced for $65.5 million with the greenshoe on Feb. 11.
The company sold 4,147,358 shares at $18.00 per share, which is a 5.96% discount to the company’s closing price on Wednesday.
Goldman Sachs & Co. and Citigroup Global Markets Inc. were the bookrunners.
Proceeds will be used for clinical development and related manufacturing, clinical trials, clinical studies, to expand and advance the company’s preclinical pipeline and for working capital and other general corporate purposes.
The biopharmaceutical company is based in Brisbane, Calif.
| Issuer: | Atara Biotherapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $74,652,444 (including $9,162,450 greenshoe)
|
| Shares: | 4,147,358
|
| Price: | $18.00
|
| Warrants: | No
|
| Bookrunners: | Goldman Sachs & Co., Citigroup Global Markets Inc.
|
| Co-manager: | Jefferies LLC
|
| Announcement date: | Jan. 28
|
| Pricing date: | Feb. 11
|
| Settlement date: | Feb. 18
|
| Stock ticker: | Nasdaq: ATRA
|
| Stock price: | $19.14 on Feb. 11
|
| Market capitalization: | $478.93 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
